Mylan N.V. (NASDAQ: MYL) revealed Friday the launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart Capsules in the United States. The company got the ultimate approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product. That is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reducing the risk of acute urinary retention and the risk of the need for BPH-related surgery.
Mylan indicated it might also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate. The company added that Dutasteride Capsules, 0.5 mg, had sales of about $297.2 million in the United States for the 12 months ending April 30, 2016.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The company quoted IMS Health and said it has 248 ANDAs pending FDA approval representing $107.6 billion in annual brand sales. The company added that forty-three of these pending ANDAs have the potential first-to-file opportunities, representing $37.2 billion in annual brand sales, for the 12 months ending December 31, 2015.
Shares of the company traded 5.94 percent down on Friday.